Novartis’ single pill combination of aliskiren and amlopidine – Tekamlo – has been approved by the Food and Drug Administration (FDA) for the treatment of hypertension. Data revealed that Tekamlo significantly reduced blood pressure compared to amlodipine or aliskiren (Tekturna) alone. The medication has been approved in tablet form.
Read full article at medical news today.
Related posts:
- Seven Influenza Vaccines For Coming Season Approved By FDA
- FDA Again Warns Apotex Corp., a Generic Maker, About Conditions at Its Plants
- Sigma Pharmaceuticals CEO Quits on “Disappointing” Performance
